Provexis

Provexis develops and commercializes Fruitflow®, a patented natural tomato extract shown in human trials to reduce platelet aggregation—a risk factor for cardiovascular events—without the side effects associated with aspirin. The product has received an EFSA-approved health claim for maintaining normal platelet aggregation. Additional research supports its use in blood pressure management, exercise-induced inflammation mitigation, protection from air pollution’s cardiovascular effects, and modulation of the gut microbiome. The company partners with DSM for commercialization outside China and BYHEALTH for distribution in China. Clinical results show efficacy comparable to low-dose aspirin but with reversible action and no major side effects.